Literature DB >> 28428066

Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses.

Sukmo Kang1, Sukyung Ahn1, Jeewon Lee2, Jin Yong Kim2, Minsuk Choi1, Vipul Gujrati1, Hyungjun Kim1, Jinjoo Kim1, Eui-Cheol Shin3, Sangyong Jon4.   

Abstract

Although it has been shown that the size of nanoparticle-based vaccines is a key determining factor for the induction of immune responses, few studies have provided detailed analyses of thresholds or critical sizes of nanoparticle vaccines. Here we report effects of the size of gold nanoparticle (GNP)-based vaccines on their efficiency of delivery to lymph nodes (LNs) and induction of CD8+ T-cell responses. We further propose a threshold size of GNPs for use as an effective vaccine. To examine the effects of GNP size, we synthesized GNPs with diameters of 7, 14 and 28nm, and then conjugated them with recombinant ovalbumin (OVA) as a model antigen. The resulting OVA-GNPs had hydrodynamic diameter (HD) of ~10, 22, and 33nm for 7, 14 and 28nm GNPs, respectively and exhibited a size-dependent increase in cellular uptake by dendritic cells (DCs) and subsequent T-cell cross-priming and activation. Upon injection into a mouse footpad, both 22- and 33-nm OVA-GNPs showed much higher delivery efficiency to draining LNs than did 10-nm OVA-GNPs. An ex vivo restimulation assay using OVA as an antigen revealed that frequencies of OVA-specific CD8+ T cells were higher in mice immunized with 22- and 33-nm OVA-GNPs than in those immunized with 10-nm OVA-GNPs; moreover, these cells were shown to be poly-functional. In a tumor-prevention study, 22-nm OVA-GNPs showed greater antitumor efficacy, and higher infiltration of CD8+ T-cells and greater tumor cell apoptosis and cell death than 10-nm OVA-GNPs. Taken together, our results suggest that the size threshold for induction of potent cellular responses and T-cell poly-functionality by GNPs lies between 10nm and 22nm, and highlight the importance of nanoparticle size as a critical parameter in designing and developing nanoparticle-based vaccines.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Cellular immunity; Cross presentation; Gold nanoparticles; Nanoparticle vaccines; Vaccines

Mesh:

Substances:

Year:  2017        PMID: 28428066     DOI: 10.1016/j.jconrel.2017.04.024

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  33 in total

Review 1.  Nanoparticle systems for cancer vaccine.

Authors:  Ru Wen; Afoma C Umeano; Yi Kou; Jian Xu; Ammad Ahmad Farooqi
Journal:  Nanomedicine (Lond)       Date:  2019-02-26       Impact factor: 5.307

Review 2.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

Review 3.  Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease.

Authors:  Katherine A Roach; Aleksandr B Stefaniak; Jenny R Roberts
Journal:  J Immunotoxicol       Date:  2019-12       Impact factor: 3.000

4.  Critical Size Limit of Biodegradable Nanoparticles for Enhanced Lymph Node Trafficking and Paracortex Penetration.

Authors:  Gregory P Howard; Garima Verma; Xiyu Ke; Winter M Thayer; Timothy Hamerly; Victoria K Baxter; John E Lee; Rhoel R Dinglasan; Hai-Quan Mao
Journal:  Nano Res       Date:  2019-01-29       Impact factor: 8.897

Review 5.  Nanomedicine and macroscale materials in immuno-oncology.

Authors:  Qingxue Sun; Matthias Barz; Bruno G De Geest; Mustafa Diken; Wim E Hennink; Fabian Kiessling; Twan Lammers; Yang Shi
Journal:  Chem Soc Rev       Date:  2019-01-02       Impact factor: 54.564

6.  Real-Time Imaging of Vaccine Biodistribution Using Zwitterionic NIR Nanoparticles.

Authors:  Wataru Katagiri; Jeong Heong Lee; Marc-André Tétrault; Homan Kang; Sinyoung Jeong; Conor L Evans; Shinya Yokomizo; Sheena Santos; Catherine Jones; Shuang Hu; Georges El Fakhri; Kosuke Tsukada; Hak Soo Choi; Satoshi Kashiwagi
Journal:  Adv Healthc Mater       Date:  2019-06-05       Impact factor: 9.933

7.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

Review 8.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

Review 9.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

10.  Lymph-directed nitric oxide increases immune cell access to lymph-borne nanoscale solutes.

Authors:  Lauren F Sestito; Susan N Thomas
Journal:  Biomaterials       Date:  2020-09-18       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.